Analysts’ Ratings for Athenex and Its Peers in March

Athenex (ATNX) is a global biopharmaceutical company. Athenex focuses on developing and commercializing therapies to treat cancer. The company has generated a pipeline of product candidates through its Orascovery and Src Kinase inhibition platforms. Athenex thinks that its oral administration can overcome the limitations of giving medicine intravenously. Athenex thinks that its Orascovery platform can deliver new approaches for using oral anti-cancer drugs.

Of the six analysts covering Athenex in March 2018, five analysts gave the stock a “buy” rating, while one analyst gave it a “hold” rating. The mean rating for the stock is 2.17 with a target price of $27.83.

Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one analyst gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave it a “hold” rating. The mean rating for the stock is 2.11 with a target price of $86.13.

Of the nine analysts covering Akebia Therapeutics (AKBA) in March 2018, one analyst gave the stock a “strong buy” rating, seven analysts gave it a “buy” rating, and one analyst gave it a “hold” rating. The mean rating for the stock is 2 with a target price of $22.11.

Of the 22 analysts covering Eli Lilly (LLY) in March 2018, 13 analysts gave the stock a “buy” or higher rating, seven analysts gave it a “hold” rating, and two analysts gave it a “sell” rating. The mean rating for the stock is 2.2 with a target price of $91.29.

Next, we’ll discuss Athenex’s research platforms and product candidates.